转移性三阴性乳腺癌的新型药物治疗进展

Advances in the novel treatment of metastatic triple-negative breast cancer

三阴性乳腺癌(triple-negative breast cancer,TNBC)侵袭性强,易复发和转移。与其他类型的乳腺癌相比,TNBC早期复发风险更高,预后更差。由于缺乏特异的治疗靶点,目前国内对转移性TNBC(metastatic TNBC,mTNBC)的一线治疗推荐仍以蒽环或紫衫醇(paclitaxel)为基础的单药或联合化疗为主。近年来,随着新型治疗药物在mTNBC中的成功应用,国外已批准一些新型药物用于mTNBC的治疗。该文拟对近年来mTNBC分子分型、免疫以及抗体药物偶联物的研究进展作一综述。

Triple-negative breast cancer(TNBC)is aggressive,prone to recurrence and metastasis.There is a higher risk of early recurrence and a worse prognosis compared to other types of breast cancer.Due to the lack of specific therapeutic targets,the first-line treatment recommendations for metastatic TNBC(mTNBC)in China are still mainly based on anthracycline or paclitaxel as monotherapy or combination chemotherapy.In recent years,with the successful application of new therapeutic drugs in mTNBC,some new drugs have been approved for the treatment of mTNBC abroad.This article reviewed the recent advances in mTNBC molecular typing,immunity and antibody drug conjugations.